Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 181 | 26 | 154 |
| Samples | 170 | 26 | 143 |
| Peptides | 140 | 17 | 123 |
Function
B3GALT2 · Beta-1,3-galactosyltransferase 2
This gene is a member of the beta-1,3-galactosyltransferase (beta3GalT) gene family. This family encodes type II membrane-bound glycoproteins with diverse enzymatic functions using different donor substrates (UDP-galactose and UDP-N-acetylglucosamine) and different acceptor sugars (N-acetylglucosamine, galactose, N-acetylgalactosamine). The beta3GalT genes are distantly related to the Drosophila Brainiac gene and have the protein coding sequence contained in a single exon. The beta3GalT proteins also contain conserved sequences not found in the beta4GalT or alpha3GalT proteins. The carbohydrate chains synthesized by these enzymes are designated as type 1, whereas beta4GalT enzymes synthesize type 2 carbohydrate chains. The ratio of type 1:type 2 chains changes during embryogenesis. By sequence similarity, the beta3GalT genes fall into at least two groups: beta3GalT4 and 4 other beta3GalT genes (beta3GalT1-3, beta3GalT5). This gene encodes a protein that functions in N-linked glycoprotein glycosylation and shows strict donor substrate specificity for UDP-galactose. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000367434 | O43825 | 181 | 140 |
Gene Properties
Recurrent Mutations
All 140 amino-acid changes on canonical ENST00000367434 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in B3GALT2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in B3GALT2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 15/612 2% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Melanoma | 2/210 1% | 17/1899 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 5/810 1% |
| Other Solid Cancers | 1/94 1% | 11/1515 1% |
| Medulloblastoma | 0/0 0% | 3/450 1% |
| Colorectal Carcinoma | 2/143 1% | 20/3239 1% |
| Gastric Carcinoma | 1/74 1% | 11/1809 1% |
| Bladder Carcinoma | 2/58 3% | 4/956 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 7/1390 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| Neuroendocrine Tumour | 1/154 1% | 2/577 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Ovarian Carcinoma | 1/109 1% | 2/998 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 7/2550 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Hepatocellular Carcinoma | 1/46 2% | 4/2210 0% |
| Prostate Carcinoma | 1/13 8% | 3/2105 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
| Other Blood Cancers | 1/61 2% | 4/2725 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
Mutation Distribution
Where B3GALT2 is mutated · all tissues, split by cell line vs tissue
How many mutations in B3GALT2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 181 mutations in B3GALT2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|